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More than 100 different mucosal types of human 
papillomavirus (HPV) have been identified. The existence 
of different HPV types at different sites of the human 
body was recognized in the late 1960s. Human 
papillomavirus infection is considered the most common 
sexually transmitted disease and can infect the ocular 
surface, as well (1-3). The mode of transmission of HPV 
infection to the conjunctiva in adults is considered 
autoinoculation from contaminated fingers in the 
majority of cases.  
Human papillomaviruses have been tangled in the 
pathogenesis and recurrence of conjunctival neoplasia, 
including conjunctival papillomas, conjunctival 
intraepithelial neoplasia (CIN) and even squamous cell 
carcinoma of the conjunctiva (SCCC). Human 
papillomavirus may coexist in SCCC lesions with other 
oncogenic viruses, such as the human immunodeficiency 
virus (HIV). According to their oncogenic potential, HPVs 
are divided into low - and high-risk types. The oncogenic 
properties of HPVs are attributed mainly to the viral 
oncoproteins E6 and E7. The involvement of HPV in the 
pathogenesis of pterygium remains controversial, 
although suggested by several studies using polymerase 
chain reaction (PCR) and immunohistochemical 
techniques. 
Human papillomaviruses are DNA viruses that have a 
marked tropism for squamous epithelium explaining the 
association of HPV infection with squamous cell 
papilloma of the conjunctiva. On the other hand, the role 
of HPV infection in the etiology of SCCC remains unclear 
(1-4). 
Human papillomaviruses types 6 and 11 are the most 
frequently found in conjunctival papillomas. Low-risk (LR) 
HPV 6 and HPV 11 are found in the majority of 
conjunctival papillomas along with dysplasia in several 
cases. In spite of such a dysplasia, carcinoma rarely 
develops in conjunctival papillomas. Other types found 
are HPV 33, HPV 45, and HPV 13. In addition, 6a and 45, 
 Med Hypothesis Discov Innov Ophthalmol. 2015; 4(2)  
 
32 DIAGNOSIS AND TREATMENT OF HPV OCULAR SURFACE INFECTIONS 
 
two new subtypes, have been reported to be associated 
with conjunctival papilloma. On the other hand high-risk 
(HR) HPV 16 and HPV 18 have been also found in 
conjunctival papillomas; these types are strongly 
associated with the occurrence of high-grade uterine 
cervical intraepithelial neoplasia progressing to cervical 
cancer. However, according to the 2007 International 
Agency for Research on Cancer, available evidence on 
conjunctival carcinogenicity of HPV in humans is limited 
(4).  
Squamous cell carcinoma of the conjunctiva is a rare 
tumor that has been strongly linked with UV radiation 
and immunosuppression (particularly in HIV patients). 
Conjunctival intraepithelial neoplasia (CIN) is a precursor 
of SCCC but the role of HPV infection in the etiology of 
SCCC remains unclear. The DNA and mRNA of HPV 16 and 
HPV 18 corresponding to the E6 region have been 
detected in CIN. A few other studies have identified the 
presence of HPV 16 and HPV 18 in severe dysplastic 
lesions and carcinomas of the conjunctiva. HPV 6 and 
HPV 11 have also been found in severe dysplasias and 
carcinomas of the conjunctiva. In addition, mainly in HIV-
positive patients, cutaneous HPV types (commonly HPV 5 
and HPV 8) have been found in SCCC lesions. In contrast, 
a strong relationship of HPV and SCCC was not found in 
multiple other studies (4).  
Prevalence of conjunctival papillomas depends on 
geographical area, but generally is higher than that of 
conjunctival carcinomas. In some African countries with 
high HIV prevalence (i.e. Uganda, Tanzania) a possible 
role of both HPV and HIV as co-factors in SCCC 
pathogenesis has been suspected, even though 
controversial. It is noteworthy that even though there 
are no cross-sectional epidemiological studies, evidence 
suggests that people without explicit clinical presentation 
may host the virus and HPV DNA can be identified in an 
even asymptomatic conjunctiva. However, the worldwide 
dissemination of HPV infection deserves our attention for 
the successful management of ocular morbidity (5). 
We have to bear in mind that, even though conjunctival 
papillomas are not life-threatening, they may be large 
enough to be displeasing or cosmetically unacceptable 
and affect vision. Furthermore, the recurrence rate for 
infectious papillomas is high; limbal papillomas have a 
recurrent rate of 40%. Therefore, accurate diagnosis is an 
indispensable step in preventing recurrences. The major 
clinical findings indicating conjunctival papilloma are 
papillomatous lesions (of exophytic growth pattern, 
sessile or pedunculated) characterized by reiterating 
fibro-vascular cores with a geometrically arranged set of 
red dots. Squamous cell papilloma with an infectious viral 
etiology has the tendency to recur after medical and 
surgical treatment. Most papillomas are benign but 
rarely they can undergo malignant transformation what 
is visible as inflammation, keratinization, or 
symblepharon formation (6). 
The differential diagnosis of conjunctival papillomas 
includes a variety of tumors: 
1) Benign tumors of the surface epithelium (i.e.  
keratoacanthoma and actinic keratosis) 
2) Malignant lesions of the surface epithelium as 
CIN and SCCC, 
3) Conjunctival lymphomas, 
4) Vascular tumors (i.e. lymphangioma and 
capillary hemangioma), 
5) Nonpigmented conjunctival melanomas, and 
6) Secondary tumors. 
There is a diffuse variant of conjunctival squamous cell 
neoplasia that can mimic chronic conjunctivitis and the 
differential diagnosis is difficult in cases of tumor 
thickening. Therefore, a conjunctival biopsy should be 
considered in cases of conjunctivitis lasting more than 
three months. The diagnosis of squamous conjunctival 
neoplasia is typically made by biopsy and invasion 
spreading into the substantia propria beneath the 
epithelium defines these lesions as carcinomas (2, 6).    
Tumor within the conjunctival epithelium does not have 
access to the lymphatic system (no metastatic potential). 
This tumor can extend onto the cornea (avascular and 
opaque in appearance), around the limbus but rarely 
inside the eye and orbit. Squamous conjunctival 
neoplasia commonly contains characteristic corkscrew-
shaped blood vessels (6). 
The medical history, slit-lamp examination, and the 
specific clinical and histopathological features of each 
tumor are used for accurate diagnosis. In the presence of 
a papillomatous growth pattern along with koilocytosis 
(nuclear pyknosis and cytoplasmic clearing), the 
morphological hallmark of HPV infection and mild 
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epithelial dysplastic changes, further laboratory 
investigation to confirm the clinical diagnosis of HPV 
infection must be performed. Therefore, 
Immunohistochemical staining, in situ hybridization and 
PCR are the appropriate laboratory procedures in the 
detection of HPV and combination of the mentioned 
methods increases the diagnostic reliability (2, 5). 
Immunohistochemical staining concerns the detection of 
HPV and p16 protein. The p16 INK4a (p16) is a cyclin-
dependent kinase inhibitor and shows marked 
overexpression in cancerous and precancerous cervical 
lesions caused by persistent infections with HR HPV 
types. Immunohistochemical staining of the biopsy 
specimens is a natural crucial step regarding 
conventional histopathological findings in HPV infections. 
It is possible to directly isolate HPV DNA from a biopsy 
specimen with in situ hybridization (ISH). This method, 
whatsoever, needs a large quantity of purified DNA, and 
its sensitivity is relatively limited, especially in obtaining 
cells from the ocular surface via non invasive 
methodologies (for example exfoliation cytology 
techniques). In cases where the biopsy specimen is small 
with a limited quantity of HPV DNA, nucleic acid 
amplification assays can be used to increase the 
sensitivity and specificity of the test. Therefore, the 
material provided by invasive methods is preferred for 
laboratory examination of conjunctival lesions with 
suspected HPV infection (5). 
Hybrid Capture II (HC-II) is a non radioactive signal 
amplification technique, accurate for mucosal lesions but 
is not appropriate for genotyping; it is useful in 
distinguishing HR from LR HPV types. Conversely, due to 
its high sensitivity, PCR is frequently associated with a 
high frequency of false-positive results. Southern blot, 
dot blot, reverse dot blot, digestion with restriction 
endonucleases or direct sequence analysis performed 
after DNA amplification can help increase the sensitivity 
and specificity of the test. More specifically real-time PCR 
or quantitative PCR (qPCR) permits rapid detection and 
quantification of the material during the various cycles of 
the PCR process (real time), considered the first choice 
assay for the detection of viral gene expression (5, 7). 
However, the technique of sample collection, affecting 
the quantity of the HPV DNA of the isolated sample, and 
the use of various HPV DNA detection techniques with 
different sensitivity and specificity, are factors that may 
determine the detection rates of HPV infections. 
Combination of the described methods increases the 
rates of HPV detection. Nevertheless, it is imperative that 
a careful excision of the lesion and appropriate fixation 
of the specimen are preconditions for success of the 
diagnostic procedure. An excisional biopsy is preferred to 
an incisional biopsy whenever possible and consultation 
with a general pathologist or, ideally, an ophthalmic 
pathologist is compulsory. Performing an excisional 
biopsy is recommended to exclude premalignancy in 
adults (6). 
Regarding squamous cell neoplasia, the lesion is removed 
surgically. After that, cryotherapy is applied to the 
adjacent conjunctiva and appears to be an effective 
technique, especially for squamous cell papillomas. 
Carbon dioxide (CO2) laser has also been used, what 
allows for precise tissue excision with minimal trauma 
and blood loss. Rapid healing occurs without significant 
scarring, edema, or symblepharon formation. Recurrence 
is low, resulting from the destruction of viral particles 
and papillomatous epithelial cells. Mitomycin-C (MMC) is 
an antineoplastic agent applied as 0.2 or 0.3 mg/mL dose 
via a cellulose sponge to the involved area(s) after 
surgical excision. The sponge is held in place for 3 
minutes followed by meticulous irrigation. It is adjuvant 
to surgical removal but is also indicated for recalcitrant 
conjunctival papillomas or those refractive to previous 
multiple treatments; it is sometimes even administered 
to prevent recurrences   of CIN and SCCC. In addition, 
amniotic membrane transplantation is used to restore 
extended conjunctival defects (2). In spite of MMC’s 
effectiveness and its setting up as a therapy asset, one 
should always keep in mind the potential of some rare 
complications such are symblepharon, corneal edema, 
corneal perforation, iritis, cataract, and glaucoma. 
Therefore, a close follow-up is recommended. 
Beside surgical approach additional treatments concern 
(6): 
1) Cimetidine (H2-receptor antagonist), indicated for 
recalcitrant and quite large conjunctival papillomas; 
cimetidine has been also found to enhance the immune 
system by inhibiting suppressor T-cell function and 
augmenting delayed-type hypersensitivity responses. 
2) Interferon is an adjunct therapy to surgical excision of 
nonrecurring or recurrent multiple lesions. Alpha 
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interferon is given intramuscularly for several months. 
Because of its antiviral and antiproliferative properties, 
this form of therapy is designed to suppress tumor cells. 
Additionally, topical interferon alpha-2b has been shown 
to be an effective adjunct therapy for small-to-medium 
size lesions but not for large lesions without surgical 
excision. Topical interferon alpha-2b can be utilized as an 
adjunctive therapy for recurring conjunctival papilloma 
and it is successful in treating also CIN lesions. 
3) Dinitrochlorobenzene (DNCB), an immune modulator, 
may induce delayed hypersensitivity reaction causing the 
tumor to regress. The mechanism is not known. DNCB is 
applied directly to the papilloma once the patient has 
been sensitized to DNCB. This treatment modality is 
reserved for cases when surgical excision, cryoablation, 
and other treatment modalities fail (8). 
Concerning squamous cell papillomas, the prognosis is 
generally good. However, recurrences of viral papilloma 
are not uncommon. On the other hand, recurrences of 
completely excised squamous cell papillomas are 
uncommon. 
Surgical excision alone of CIN and SCCC lesions has been 
associated with frequent recurrences. This is because the 
tumor's edges and deep margins (often clear and 
avascular) are generraly difficult to determine, 
misleading the operator pretending the tumor is smaller 
than it is. Local freezing of the tumor nest (sclera and 
adjacent conjunctiva) has improved local management 
and decreased the incidence of tumor’s recurrence (2). 
According to another approach, radiation therapy is 
administered to decrease tumor’s recurrence rate. In 
addition, topical chemotherapy, or "chemotherapy eye 
drops" have been found effective in several clinical trials. 
Therefore, large clinical trial is needed to compare the 
effectiveness of topical chemotherapy to excision, 
cryotherapy and combinations (6). 
Intraocular penetration of tumor is extremely rare in 
developed societies; it is typically treated by enucleation 
of the eye or eye-wall resection. Orbital invasion brings 
along the risk of spread into the sinuses and brain, the 
most common cause of death related to this tumor. 
When squamous conjunctival neoplasia metastasizes 
outside of the eye and orbit, it can affect regional lymph 
nodes (preauricular, submandibular, and cervical) or/and 
the lungs and bone. In general, early detection allows for 
removal of these tumors with excellent local cure rates. 
Outdoor occupation, living close to the equator, 
tendency to sunburns and history of actinic skin lesions 
are risk factors. Theoretically, decreasing of sun exposure 
may prevent squamous cell lesions (6).  
As already mentioned, the role of HPV infection in 
human eye disease is controversial, but it is likely that 
HPV6/11 plays a role in the pathogenesis of conjunctival 
papilloma (2, 7). However, some cases illustrate the 
possible role of HPV in SCCC and the potentially 
devastating effects of this disease. The development of 
two vaccines, for prophylaxis from HPV infection 
concerning the types most commonly associated with 
anogenital cancers, has trigerred controversies with 
regard to the real benefit by a national immunization 
program to prevent cervical cancer. It seems that the 
greatest benefit in eye disease would be achieved 
administering the quadrivalent vaccine. The impact of 
the quadrivalent prophylactic vaccine against HPV types 
6, 11, 16, and 18 on all HPV-associated genital disease 
was investigated in a population of sexually 
inexperienced (HPV-unexposed) women. Prophylactic 
vaccination was 95%–100% effective in reducing HPV 16 
and 18 types related high-grade cervical, vulvar, and 
vaginal lesions and 97% effective in reducing HPV 6 and 
11 types related genital warts (9). 
Thus, in ophthalmology, the quadrivalent vaccine is 
expected to decrease the incidence of conjunctival 
papillomas due to HPV infection. In contrast, the HPV 
vaccination is not expected to prevent SCCC because HPV 
is not the main oncogenic agent in SCCC. Nevertheless, it 
will take many years before the benefits of a vaccination 
program become apparent, because even though 
papillomas occur in a relatively young, conjunctival 
carcinoma is usually a disease of the elderly (9). 
 In addition, despite controversies in the medical 
literature concerning HPV involvement in pterygium 
development, the results of most studies agree that HPV 
is detected in at least a subgroup of pterygia. In these 
cases HPV infection may affect both pathogenesis and 
clinical behavior (including recurrence) of pterygium (10). 
Therefore, it would be interesting to explore the 
possibility of antiviral medications or even vaccination, 
which may represent novel options in the therapy of 
selected HPV-infected pterygia.  
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However, clinicians should be aware of a possible 
bilateral uveitis and papillitis following HPV vaccination 
(11). Multiple transitory white dots of the retina as a 
manifestation of multiple evanescent white dot 
syndrome (MEWDS) have also been reported in the early 
period after HPV vaccination. 
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